amg 570
mAbexperimentalMulti-specific
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2016 (NCT02618967)
Timeline
Indications
Mechanism of action
TNFSF13B inhibitor
- ICOS ligandINHIBITOR
ICOSLG inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- amg 570
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04058028 | Phase 2 | Sep 2, 2019 | Amgen |
| NCT03156023 | Phase 1 | Jun 20, 2017 | Amgen |
| NCT02618967 | Phase 1 | Mar 1, 2016 | Amgen |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 3 | 3 | 2 | 2016 |
1 organizations
Page 1 / 1